Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

exelixis inc. - EXEL

EXEL

Close Chg Chg %
36.54 -0.18 -0.49%

Open Market

36.36

-0.18 (0.49%)

Volume: 209.18K

Last Updated:

Apr 16, 2025, 10:06 AM EDT

Trade Now

Company Overview: exelixis inc. - EXEL

EXEL Key Data

Open

$36.38

 Day Range

36.14 - 36.67

52 Week Range

20.14 - 40.00

 Market Cap

$10.23B

Shares Outstanding

279.88M

 Public Float

270.46M

Beta

0.57

 Rev. Per Employee

N/A

P/E Ratio

20.76

 EPS

$1.81

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.74M

  

EXEL Performance

1 Week
 
 3.48%
 
1 Month
 
 -0.30%
 
3 Months
 
 0.94%
 
1 Year
 
 62.26%
 
5 Years
 
 87.96%
 

EXEL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About exelixis inc. - EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

EXEL At a Glance

Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda, California 94502
Phone 1-650-837-7000 Revenue 2.17B
Industry Pharmaceuticals: Major Net Income 521.27M
Sector Health Technology 2024 Sales Growth 18.495%
Fiscal Year-end 12 / 2025 Employees 1,147
View SEC Filings

EXEL Valuation

P/E Current 20.06
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 19.208
Price to Sales Ratio 4.617
Price to Book Ratio 4.244
Price to Cash Flow Ratio 14.304
Enterprise Value to EBITDA 12.684
Enterprise Value to Sales 4.204
Total Debt to Enterprise Value 0.024

EXEL Efficiency

Revenue/Employee 1,890,759.372
Income Per Employee 454,461.203
Receivables Turnover 7.736
Total Asset Turnover 0.725

EXEL Liquidity

Current Ratio 3.635
Quick Ratio 3.579
Cash Ratio 2.752

EXEL Profitability

Gross Margin 96.486
Operating Margin 31.814
Pretax Margin 31.431
Net Margin 24.036
Return on Assets 17.424
Return on Equity 23.126
Return on Total Capital 21.189
Return on Invested Capital 21.325

EXEL Capital Structure

Total Debt to Total Equity 9.617
Total Debt to Total Capital 8.774
Total Debt to Total Assets 7.226
Long-Term Debt to Equity 8.503
Long-Term Debt to Total Capital 7.757
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Exelixis Inc. - EXEL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.43B 1.61B 1.83B 2.17B
Sales Growth
+45.31% +12.27% +13.60% +18.49%
Cost of Goods Sold (COGS) incl D&A
52.87M 57.91M 72.55M 76.22M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
13.63M 20.88M 25.72M 28.80M
Depreciation
13.63M 20.88M 25.72M 28.80M
Amortization of Intangibles
- - - -
-
COGS Growth
+45.77% +9.52% +25.28% +5.06%
Gross Income
1.38B 1.55B 1.76B 2.09B
Gross Income Growth
+45.29% +12.38% +13.17% +19.05%
Gross Profit Margin
+96.32% +96.41% +96.04% +96.49%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.10B 1.35B 1.59B 1.40B
Research & Development
693.72M 891.81M 1.04B 910.41M
Other SG&A
401.71M 459.86M 542.71M 492.13M
SGA Growth
+30.22% +23.39% +17.39% -11.61%
Other Operating Expense
- - - -
-
Unusual Expense
- (800.00K) (1.20M) 85.33M
EBIT after Unusual Expense
287.47M 202.68M 170.88M 604.62M
Non Operating Income/Expense
6.69M 31.67M 86.64M 77.02M
Non-Operating Interest Income
7.67M 33.06M 86.54M 77.16M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
294.15M 234.35M 257.52M 681.64M
Pretax Income Growth
+124.82% -20.33% +9.89% +164.69%
Pretax Margin
+20.50% +14.55% +14.07% +31.43%
Income Tax
63.09M 52.07M 49.76M 160.37M
Income Tax - Current - Domestic
- 112.43M 182.97M 219.83M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (60.36M) (133.21M) (59.46M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
231.06M 182.28M 207.76M 521.27M
Minority Interest Expense
- - - -
-
Net Income
231.06M 182.28M 207.76M 521.27M
Net Income Growth
+106.71% -21.11% +13.98% +150.89%
Net Margin Growth
+16.10% +11.31% +11.35% +24.04%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
231.06M 182.28M 207.76M 521.27M
Preferred Dividends
- - - -
-
Net Income Available to Common
231.06M 182.28M 207.76M 521.27M
EPS (Basic)
0.7338 0.5669 0.653 1.7973
EPS (Basic) Growth
+102.37% -22.74% +15.19% +175.24%
Basic Shares Outstanding
314.88M 321.53M 318.15M 290.03M
EPS (Diluted)
0.7168 0.5616 0.6463 1.7602
EPS (Diluted) Growth
+103.93% -21.65% +15.08% +172.35%
Diluted Shares Outstanding
322.36M 324.56M 321.46M 296.13M
EBITDA
300.30M 222.36M 196.60M 718.75M
EBITDA Growth
+142.11% -25.95% -11.58% +265.59%
EBITDA Margin
+20.93% +13.80% +10.74% +33.14%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 37.947
Number of Ratings 21 Current Quarters Estimate 0.469
FY Report Date 06 / 2025 Current Year's Estimate 2.024
Last Quarter’s Earnings 0.36 Median PE on CY Estimate N/A
Year Ago Earnings 1.76 Next Fiscal Year Estimate 2.38
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 17 15
Mean Estimate 0.47 0.58 2.02 2.38
High Estimates 0.57 0.65 2.44 3.10
Low Estimate 0.29 0.43 1.68 1.44
Coefficient of Variance 18.43 10.25 11.69 19.14

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 13
OVERWEIGHT 0 0 0
HOLD 10 10 9
UNDERWEIGHT 0 0 1
SELL 0 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Exelixis Inc. - EXEL

Date Name Shares Transaction Value
Mar 6, 2025 Patrick J. Haley EVP, Commercial 341,028 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.8 per share 13,231,886.40
Mar 3, 2025 Jack L. Wyszomierski Director 356,605 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $37.8 per share 13,479,669.00
Mar 3, 2025 Julie Anne Smith Director 19,294 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Julie Anne Smith Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Julie Anne Smith Director 10,778 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $37.62 per share 405,468.36
Mar 3, 2025 Julie Anne Smith Director 30,072 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $19.77 per share 594,523.44
Mar 3, 2025 Julie Anne Smith Director 10,778 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.13 per share 410,965.14
Mar 3, 2025 Julie Anne Smith Director 65,292 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $19.77 per share 1,290,822.84
Mar 3, 2025 Julie Anne Smith Director 41,945 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $20.5 per share 859,872.50
Mar 3, 2025 Jeffrey J. Hessekiel EVP & General Counsel 597,608 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Christopher J. Senner EVP and CFO 839,255 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Amy C. Peterson EVP Prod Dev & Med Aff & CMO 347,089 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Michael M. Morrissey President and CEO; Director 1,033,290 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Julie Anne Smith Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Dana T. Aftab CSO/EVP Disc & Trans Research 561,117 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Jack L. Wyszomierski Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Jack L. Wyszomierski Director 365,373 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $20.5 per share 7,490,146.50
Feb 27, 2025 Michael M. Morrissey President and CEO; Director 1,764,985 Bona fide gift 0.00
Feb 27, 2025 Christopher J. Senner EVP and CFO 779,607 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $36.14 per share 28,174,996.98
Feb 27, 2025 Christopher J. Senner EVP and CFO 100,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Exelixis Inc. in the News